International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, announced today the following near-term events as part of its ongoing efforts to increase scientific awareness of the Company, its proprietary Parthenogenic Stem Cell Lines, and their potential uses in research and therapy:
- Kenneth Aldrich, Chairman of ISCO, will participate in two panel discussions regarding biotech funding and exit strategies at the "Cell and Gene Therapy Forum 2010" in Washington DC on January 25 and 26, 2010 (www.phacilitate.co.uk/pages/cgtherapy/).
- Brian Lundstrom, President of ISCO, will present the company and its Asian partnering opportunities in cell culture products, cornea transplantation and universal stem cells at "BIO Asia Partnering" in Tokyo on January 26, 2010. (http://bioasia.bio.org/opencms/bioasia/2010/).
- Mr. Aldrich will provide a webinar on ISCO's strategy and 2010 plans on February 5, 2010. Participation details will be available on the company's web site before the event and the web cast will be posted on the site afterward.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman 760-940-6383
Brian Lundstrom, President 760-640-6383
The Investor Relations Group 212-825-3210
Media Relations:Laura Colontrelle
Investor Relations:James Carbonara